Protarga, Inc. v. Webb (In Re Protarga, Inc.)

329 B.R. 451, 2005 Bankr. LEXIS 1694, 2005 WL 2190260
CourtUnited States Bankruptcy Court, D. Delaware
DecidedSeptember 1, 2005
Docket19-10282
StatusPublished
Cited by6 cases

This text of 329 B.R. 451 (Protarga, Inc. v. Webb (In Re Protarga, Inc.)) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Protarga, Inc. v. Webb (In Re Protarga, Inc.), 329 B.R. 451, 2005 Bankr. LEXIS 1694, 2005 WL 2190260 (Del. 2005).

Opinion

*455 MEMORANDUM OPINION

PETER J. WALSH, Bankruptcy Judge.

This is the Court’s ruling following a six-day trial on Protarga, Inc. fik/a Neu-romediea, Inc.’s (“Protarga”) complaint objecting to Nigel L. Webb’s (“Webb”) proof of claim and asserting counterclaims. 1 Webb’s proof of claim is based on an employment contract. For the reasons set forth below, the Court finds in part for Protarga and in part for Webb.

BACKGROUND

From its inception in 1991, Protarga was a start-up drug development company. The company hired Webb in 1993. Pro-targa and Webb entered into three successive employment agreements, one in 1993, one in 1997 and the last one in 2001. The 2001 employment agreement (the “Employment Agreement”), was for a five-year term starting on June 1, 2001 and ending on May 31, 2006. The Employment Agreement has a number of alternative severance payment packages, each being dependent on the circumstances of Webb’s employment termination. Also, in 1993 Protarga and Webb executed an intellectual property agreement (the “IP Agreement”) pursuant to which all of Webb’s “inventions” during his employment would become the property of Protarga. The IP Agreement has rather conventional terms typical of such agreements that are widely used by companies engaged in developing new products or systems.

From 1993 until July 2003, Webb served as president and chief executive officer of Protarga. In August 2000, Webb was elected chairman of Protarga’s board of directors (the “Board”), and served in that position until July 31, 2003. He continued to serve as a Board member until August 21, 2003.

Protarga had developed a few promising anti-cancer drugs that were in phase 2 clinical trials during 2001. From its founding in 1991 through 2002 Protarga financed its development operations with a combination of debt and equity funds totaling approximately $57 million. (Doc. # 480, p. 15.) 2 In 2001 Protarga embarked on an initial public offering of its stock (the “IPO”). It filed its registration statement with the Securities and Exchange Commission in December 2001. It continued moving forward on this track until it became clear in 2002 that the market conditions would prevent a successful IPO. Protarga was forced to withdraw its registration statement in October 2002. From that point on its financial condition deteriorated dramatically.

During the spring of 2003 Protarga began negotiating an agreement with Spectrum Pharmaceuticals, Inc. (“Spectrum”) pursuant to which Spectrum would be the stalking horse bidder for all of Protarga’s assets after Protarga filed for bankruptcy relief. Protarga’s management was sharply divided on this course of action, with Webb opposing it.

In an effort to address its liquidity crisis, in June 2003, Protarga offered its employees a temporary salary reduction so that it could continue operating. Webb *456 accepted this offer and was granted additional stock options to purchase 72,000 shares of the company’s stock with an exercise price of $0.01. In July 2003, Pro-targa was still having serious financial problems and it offered its employees a furlough proposal pursuant to which the employees would forego their salary but continue working. Webb rejected this offer on July 24, 2003 and asserts that as of that date his employment was terminated without cause.

After July 24, 2003, Protarga asserts that it discovered disturbing evidence relating to Webb’s work on a personal project of his that improperly diverted Protar-ga personnel and resources. That project was the construction and furbishing of a luxurious home in the Bahamas. The home is owned by defendant Five Palms Corporation, Ltd. (“Five Palms”). Five Palms is a corporation owned and controlled by Webb and members of his family. On August 22 and 26, 2003 the Board passed resolutions terminating Webb for cause.

On August 14, 2003, Protarga filed a voluntary petition under chapter 11 of title 11 of the United States Code, 11 U.S.C. §§ 101 et seq. (the “Bankruptcy Code”). 3

Following the bankruptcy filing, in September 2003, Protarga’s business was exposed to an auction sale process. The stalking horse, Spectrum, was not the highest bidder. The business was sold to Luitpold Pharmaceuticals, Inc. (“Luit-pold”), a subsidiary of a large Japanese pharmaceutical company, in a sale that closed on October 20, 2003. Luitpold purchased Protarga’s business for $7.5 million plus a structure that provides additional future payments to Protarga in the event milestones are achieved related to drug development programs that Luitpold acquired from Protarga. (Doc. # 480, p. 15.) This sale transaction produced a “change of control” as contemplated by the Employment Agreement, which event significantly enhanced the amount that Webb could receive as a severance package.

On November 29, 2004 Protarga’s disclosure statement (the “Disclosure Statement”) was approved. On January 14, 2005 Protarga’s plan of reorganization (the “Plan”) was confirmed. The Plan calls for a combination of cash distributions and participation arrangements for claimants.

The instant matter involves a disputed proof of claim that has been amended a number of times by Webb. On October 29, 2003, Webb filed his initial proof of claim in the amount of $2,642,609.75. (Claim # 28.) Subsequently, on December 10, 2004, Webb amended his proof of claim and increased the amount sought to $2,803,996.12. (Claim # 179.) Immediately prior to the trial on this matter, Webb filed his latest amendment to the proof of claim on June 1, 2005 in which he increased the amount sought to $2,931,191.07. (Claim #245.) Webb’s claim of $2,931,191.07 consists of the following: (1) the Employment Agreement severance package of $2,058,299.98, (2) a 25% “liquidated damages” claim under the Pennsylvania Wage Payment and Collection Law (the “WPCL”), 43 Pa. Stat. Ann. §§ 260.1 et seq. (West 2005), in the amount of $514,574.97 and (3) attorneys’ fees and costs (as allowed for a successful claimant under the WPCL) of $358,316.22. 4 Even as to this latest proof of claim, Webb asserts that there are amounts that have yet to be determined and that there will be *457 additional attorneys’ fees sought. 5 (Claim # 245, p. 4.)

In December 2004 Webb filed a complaint in the Court of Common Pleas for Philadelphia County against Robert Dickey, IV (“Dickey”), an officer and director of Protarga, and John E. Koerner, III (“Koerner”), a director of Protarga, in which he alleges that, pursuant to the WPCL, these two defendants are obligated to pay him for the same claim as he asserts here. Webb’s state law complaint also asserts a count for defamation. The state court action has not yet gone to trial.

Aside from bankruptcy law considerations, the amount of Webb’s entitlement turns on whether he was terminated for cause or without cause.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re: 21st Century Oncology Holdings, Inc.
965 F.3d 196 (Second Circuit, 2020)
In Re Verasun Energy Corp.
467 B.R. 757 (D. Delaware, 2012)
In Re WorldCom, Inc.
361 B.R. 675 (S.D. New York, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
329 B.R. 451, 2005 Bankr. LEXIS 1694, 2005 WL 2190260, Counsel Stack Legal Research, https://law.counselstack.com/opinion/protarga-inc-v-webb-in-re-protarga-inc-deb-2005.